Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.

Cancer medicine - 1 Apr 2018

Chen Juan, Cui Jie-da, Guo Xiao-Tong, Cao Xia, Li Qing

Abstract excerpt

Epidermal growth receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) have emerged as first-line drugs for advanced non-small-cell lung cancer (NSCLC) patients with EFGR mutations. However, most patients with NSCLC show acquired resistance to EGFR-TKIs, and low expression of NF1 is a mechanism of EGFR-TKI resistance in lung cancer. However, the mechanism by which NF1 is downregulated in EGFR-TKI-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to MAP Kinase Signaling System

Share to MicroRNAs

Share to Neurofibromatosis 1

Share to RNA Interference

Source

Open in PubMed Open full text

Identifiers

PMID: 29493886
DOI: 10.1002/cam4.1326
PMCID: PMC5911582

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.PMID 29493886Read ↗

MicroRNA‑103a‑3p potentiates chemoresistance to cisplatin in non‑small cell lung carcinoma by targeting neurofibromatosis 1Semantic proximity Read ↗

Advancement in research and therapy of NF1 mutant malignant tumorsSemantic proximity Read ↗

Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.Semantic proximity Read ↗

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancersSemantic proximity Read ↗

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLCSemantic proximity Read ↗

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.Semantic proximity Read ↗

Knockdown of TRAF1 in NSCIC Contributes Gefitinib Sensitivity by Promoting G2/M Cell Cycle ArrestSemantic proximity Read ↗

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancerSemantic proximity Read ↗

MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Paths of resistance to EGFR inhibitors: is NF enough?Semantic proximity Read ↗

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.